Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/059030external-prioritypatent/WO2010007082A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of TN2010000599A1publicationCriticalpatent/TN2010000599A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Antibodies that specifically bind to the BAFF receptor (BAFFR). More specifically antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.
TNP2010000599A2009-07-152010-12-24Compositions and methods of use for therapeutic antiodies
TN2010000599A1
(en)
Compositions comprising cd19xcd3 bispecific antibodies for the treatment of tumorous mass of lymph node tissue and/or extranodal lymphoma caused by diffuse large b cell lymphoma (dlbcl)